We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$881M
1-Year Est. Return
160.77%
This Fund
S&P 500
This Quarter
Est. Return
-4.67%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$739M
AUM Growth
-$91.7M
(-11%)
Cap. Flow
-$6.12M
Cap. Flow
% of AUM
-0.83%
Top 10 Holdings %
Top 10 Hldgs %
94.94%
Holding
17
New
–
Increased
6
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$783K |
| 2 |
JBIO
Jade Biosciences
JBIO
|
+$515K |
| 3 |
Dianthus Therapeutics
DNTH
|
+$218K |
| 4 |
Dyne Therapeutics
DYN
|
+$207K |
| 5 |
TECX
Tectonic Therapeutic
TECX
|
+$23.8K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$4.08M |
| 2 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
+$3.79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kymera Therapeutics
KYMR
$9.74B
| $174M | 23.5% |
5,858,262
-126,474
| -2% | -$4.08M |
|
|
2
Dyne Therapeutics
DYN
$3.2B
| $114M | 15.42% |
9,885,449
+15,966
| +0.2% | +$207K |
|
|
DAWN
3
DELISTED
Day One Biopharmaceuticals
DAWN
| $102M | 13.77% |
7,608,394
+40,077
| +0.5% | +$783K |
|
4
Disc Medicine
IRON
$2.63B
| $73.4M | 9.93% |
3,461,784
| – | – |
|
|
VIGL
5
DELISTED
Vigil Neuroscience
VIGL
| $57.1M | 7.74% |
5,836,874
| – | – |
|
|
THRD
6
DELISTED
Third Harmonic Bio
THRD
| $44.9M | 6.08% |
10,907,859
| – | – |
|
|
JBIO
7
Jade Biosciences
JBIO
$1.09B
| $41.1M | 5.57% |
58,264
+621
| +1% | +$515K |
|
8
Replimune Group
REPL
$1.23B
| $37.1M | 5.02% |
2,098,300
| – | – |
|
|
GBIO
9
DELISTED
Generation Bio
GBIO
| $35.6M | 4.82% |
827,948
+60
| +0% | +$2.9K |
|
|
AKRO
10
DELISTED
Akero Therapeutics
AKRO
| $22.7M | 3.08% |
594,251
| – | – |
|
|
IMA
11
ImageneBio Inc
IMA
$58.7M
| $17.3M | 2.34% |
418,182
| – | – |
|
12
Xilio Therapeutics
XLO
$59.2M
| $8.75M | 1.18% |
197,096
| – | – |
|
|
TECX
13
Tectonic Therapeutic
TECX
$531M
| $4.54M | 0.61% |
378,448
+1,709
| +0.5% | +$23.8K |
|
|
14
Dianthus Therapeutics
DNTH
$5.49B
| $3.01M | 0.41% |
236,981
+19,697
| +9% | +$218K |
|
15
Viridian Therapeutics
VRDN
$2.49B
| $2.29M | 0.31% |
90,072
| – | – |
|
16
Spero Therapeutics
SPRO
$65.8M
| $1.5M | 0.2% |
1,031,160
| – | – |
|
|
FSTX
17
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| – | – |
-599,524
| Closed | -$3.79M |
|
Similar funds
AAA
FSCM
CCA
TAM
FFG
MWA
1IA
EPAM
Atlas Venture Life Science Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Atlas Venture Life Science Advisors held 17 positions worth $739M, down 11% from $830M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Atlas Venture Life Science Advisors's Q1 2023 filing shows 6 increased, 1 reduced and 1 closed positions. The largest sale was Kymera Therapeutics, an estimated $4.08M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Atlas Venture Life Science Advisors added most to Day One Biopharmaceuticals in Q1 2023, an estimated $783K increase.
- Atlas Venture Life Science Advisors's biggest Q1 2023 reduction was Kymera Therapeutics, cutting an estimated $4.08M.
- Atlas Venture Life Science Advisors fully exited F-star Therapeutics, Inc. Common Stock in Q1 2023, selling an estimated $3.79M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 95% of its $739M portfolio in Q1 2023.
- Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q1 2023.
- Atlas Venture Life Science Advisors's portfolio value fell 11% quarter-over-quarter to $739M.
Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2023, filed 15 May 2023.